Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Stage of Development | 8 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Therapy Area | 9 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Indication | 10 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Products under Development by Companies | 13 | 2 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Therapeutics Assessment | 15 | 7 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Companies Involved in Therapeutics Development | 22 | 5 |
| Aegerion Pharmaceuticals, Inc. | 22 | 1 |
| Ambrx, Inc. | 23 | 1 |
| Jyant Technologies, Inc. | 24 | 1 |
| Neurotez, Inc. | 25 | 1 |
| XL-protein GmbH | 26 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Drug Profiles | 27 | 16 |
| ARX-328 Drug Profile | 27 | 1 |
| CV-0801 Drug Profile | 28 | 1 |
| CV-0802 Drug Profile | 29 | 1 |
| memtin Drug Profile | 30 | 2 |
| metreleptin Drug Profile | 32 | 5 |
| Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders Drug Profile | 37 | 1 |
| Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer Drug Profile | 38 | 1 |
| Recombinant Protein to Agonize Leptin Receptor for Alzheimer's Disease Drug Profile | 39 | 1 |
| Recombinant Protein to Agonize Leptin Receptor for Obesity Drug Profile | 40 | 1 |
| Synthetic Peptide to Agonize Leptin Receptor for Diabetes and Obesity Drug Profile | 41 | 1 |
| XL-100 Drug Profile | 42 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Dormant Projects | 43 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Discontinued Products | 44 | 1 |
| Leptin Receptor (OB Receptor or CD295 or LEPR) Featured News &Press Releases | 45 | 10 |
| Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease | 45 | 1 |
| Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin | 46 | 1 |
| Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin | 46 | 1 |
| May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy | 47 | 1 |
| Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy | 48 | 1 |
| Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer s Disease | 48 | 1 |
| Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy | 49 | 1 |
| Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy | 50 | 1 |
| Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy | 51 | 1 |
| Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy | 52 | 1 |
| Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy | 53 | 1 |
| Nov 16, 2010: Juvenile Diabetes Research Foundation And Amylin Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes | 53 | 2 |
| Appendix | 55 | 2 |
| Methodology | 55 | 1 |
| Coverage | 55 | 1 |
| Secondary Research | 55 | 1 |
| Primary Research | 55 | 1 |
| Expert Panel Validation | 55 | 1 |
| Contact Us | 55 | 1 |
| Disclaimer | 56 | 1 |